Recent Press Releasess
11.12.2024
Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)
11.07.2024
Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
10.14.2024
Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline
10.04.2024
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)